Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

MLA

Dohan, Anthony, et al. “Early Evaluation Using a Radiomic Signature of Unresectable Hepatic Metastases to Predict Outcome in Patients with Colorectal Cancer Treated with FOLFIRI and Bevacizumab.” Gut, vol. 69, no. 3, Mar. 2020, pp. 531–39. EBSCOhost, https://doi.org/10.1136/gutjnl-2018-316407.

APA

Dohan, A., Gallix, B., Guiu, B., Le Malicot, K., Reinhold, C., Soyer, P., Bennouna, J., Ghiringhelli, F., Barbier, E., Boige, V., Taieb, J., Bouché, O., François, E., Phelip, J.-M., Borel, C., Faroux, R., Seitz, J.-F., Jacquot, S., Ben Abdelghani, M., … Hoeffel, C. (2020). Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. Gut, 69(3), 531–539. https://doi.org/10.1136/gutjnl-2018-316407

Chicago

Dohan, Anthony, Benoit Gallix, Boris Guiu, Karine Le Malicot, Caroline Reinhold, Philippe Soyer, Jaafar Bennouna, et al. 2020. “Early Evaluation Using a Radiomic Signature of Unresectable Hepatic Metastases to Predict Outcome in Patients with Colorectal Cancer Treated with FOLFIRI and Bevacizumab.” Gut 69 (3): 531–39. doi:10.1136/gutjnl-2018-316407.